Biomarin Pharmaceutical Inc (BMRN) Q4 2020 Earnings Call Transcript
BMRN earnings call for the period ending December 31, 2020.
BioMarin Pharmaceutical(BMRN)
Nasdaq Global Select
BMRN
$77.77
$0.66
0.9%
Price as of April 13, 2021, 8:00 p.m. EDT
View Interactive BMRN Charts
The Company develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
Interactive Chart
News & Analysis: BioMarin Pharmaceutical
The Fool has written over 200 articles on BioMarin Pharmaceutical.
Is Now A Good Time To Buy BioMarin Stock?
Shares in this biotech company are down considerably from where they were this summer, but the stock looks ready to take off again.
Biomarin Pharmaceutical Inc (BMRN) Q3 2020 Earnings Call Transcript
BMRN earnings call for the period ending September 30, 2020.
2 Healthcare Stocks That Could Double Your Money
Patient investors could double their money in these two stocks that the market has temporarily cast aside.
How BioMarin Beat Expectations in Q3
The biotech managed to overcome headwinds caused by the COVID-19 pandemic.
2020 Will Be a Year to Forget for These 3 Healthcare Stocks
Many of us want to forget this year, but investors in these three companies will be especially eager to put 2020 in the rearview mirror.
Why Nikola and BioMarin Fell While the Nasdaq Bounced
Even with a mild recovery for the markets, some stocks found themselves on the losing side.
BioMarin to Present Results of Successful Achondroplasia Study
Daily injections of vosoritide sped up growth rates for children with the most common form of dwarfism.
Is Biomarin's Disaster Bad News for Your Gene Therapy Stocks?
Getting new one-time treatments to patients who need them isn't getting any easier.
Nasdaq Falls Off Record Levels; Momenta, BioMarin Head in Opposite Directions
The Fed spoiled the party for the stock market.
